Many people search for “What does third-generation IVF mean?”—it actually refers to preimplantation genetic testing (PGT) conducted before embryo transfer. This article explains in accessible yet medically accurate terms what it addresses, who it suits, how the technology works, the process flow, and common questions.
I) Definition: “Third-Generation IVF” Essentially Means “Preimplantation Genetic Testing”
The terms “first-, second-, and third-generation IVF” commonly used in clinical settings are more colloquial labels. “Third-generation IVF” typically refers to Preimplantation Genetic Testing (PGT): After obtaining embryos through in vitro fertilization and before implantation, a small number of cells are extracted from the embryos for genetic testing. This allows for the selection and transfer of embryos with lower genetic risks.
A crucial point to clarify:
Third-generation ≠ a “superior” shortcut to higher success rates. PGT addresses “genetic risk identification/elimination” and does not equate to “improved live birth rates for everyone.” Findings on whether PGT-A (aneuploidy screening) universally boosts live birth rates vary across studies and populations, with guidelines emphasizing indication-based selection.
PGT also does not “genetically enhance children.” It primarily involves “testing and screening,” not “gene editing.”
II) Which groups are more commonly advised to consider “third-generation IVF” (PGT)?
In assisted reproductive clinics, doctors typically consider PGT based on clear genetic risks or adverse pregnancy histories. Common scenarios include:
- Confirmed family history/carrier status for single-gene hereditary diseases
e.g., thalassemia, spinal muscular atrophy (SMA): These cases typically correspond to PGT-M (monogenic disease testing), aiming to reduce the risk of passing known pathogenic variants to the next generation.
Couples where one or both partners have chromosomal structural abnormalities
Such as balanced translocations, inversions, etc.: These cases typically correspond to PGT-SR (structural rearrangement testing), used to reduce the probability of forming embryos with severe chromosomal imbalances.
Recurrent spontaneous miscarriage/implantation failure requiring chromosomal evaluation
This group may sometimes consider PGT-A (aneuploidy screening), but adoption depends on age, embryo quantity, medical history, and center policies; guidelines emphasize evidence heterogeneity and caution against “one-size-fits-all” approaches.
Women of advanced maternal age or with diminished ovarian reserve who still obtain a sufficient number of blastocysts
Biological correlation exists between advanced maternal age and increased risk of embryonic chromosomal aneuploidy; however, when “embryo numbers are very low,” the decision to perform PGT-A requires more careful consideration (testing may further reduce the number of transferable embryos).
Expert Note (Quote Box)
“PGT-A aids in identifying chromosomally abnormal embryos, but results are influenced by factors like embryonic mosaicism and sampling error. Clinical application should integrate indications with genetic counseling, avoiding its portrayal as an ‘essential’ add-on for all individuals.”
III) What the Technology Actually Does: Differences Between PGT-A / PGT-M / PGT-SR
For clarity, PGT can be categorized into three types based on their detection targets (a common clinical approach):
PGT-A: Screens for embryonic chromosomal number abnormalities (aneuploidy)
Common applications: Assesses chromosomal abnormality risk in specific populations, potentially reducing transfer failure or miscarriage risks from obvious aneuploidy. However, its impact on live birth rates requires population-specific discussion.
PGT-M: Targeted detection for “known monogenic disorders”
Prerequisite: One or both parents are confirmed carriers of a pathogenic variant (or the variant has been localized within the family). This is more akin to “targeted risk mitigation,” aiming to reduce the risk of having a child with a specific genetic disorder.
PGT-SR: Risk assessment for chromosomal structural rearrangements (e.g., translocations)
Used to identify embryos at risk due to structural rearrangements causing unbalanced chromosomal configurations.
Critical limitations (must be clearly explained clinically):
Mosaicism: Different cell lines within an embryo may exhibit varying chromosomal states. Since blastocyst biopsy samples represent only a small subset of cells, this can lead to interpretation challenges and misdiagnosis risks. This remains a key point of repeated discussion among multiple expert opinions.
Accuracy is not an “absolute value”: Different platforms, laboratory workflows, and threshold settings all influence report interpretation; therefore, genetic counseling is critical.
IV) Frequently Asked Questions: Top 4 User Inquiries
Q1: Does third-generation IVF offer “higher success rates”?
Not necessarily. PGT's value lies in reducing specific genetic risks or aiding selection, but “whether it improves live birth rates” depends on the population and treatment protocol. ASRM's committee opinion on PGT-A emphasizes: Evidence varies and has limitations; decisions should be based on indications and individual circumstances.
Q2: Does PGT-A prevent miscarriage?
PGT-A may reduce failure risks caused by obvious chromosomal aneuploidy. However, miscarriage has multiple causes (uterine factors, immune/endocrine issues, coagulation abnormalities, non-embryonic genetic factors, etc.), so “whether a miscarriage occurs” cannot be simplified to “whether PGT-A was performed.” Relevant reviews also note limitations due to technical and population variations.
Q3: Does it harm the embryo?
Blastocyst trophectoderm biopsy typically targets cells destined to form the placenta. Many centers consider risks manageable when performed by experienced teams. However, medical literature indicates that the biopsy and testing process adds steps and costs, with potential impacts on embryo viability and misinterpretation risks—factors requiring careful consideration.
Q4: Can embryos labeled “mosaic” in reports still be transferred?
This is a highly specialized question typically requiring joint assessment by genetic counseling and reproductive centers. ASRM has provided a discussion framework specifically for the clinical management of “PGT-A mosaic results,” emphasizing that mosaicism may lead to misinterpretation and interpretation difficulties, necessitating cautious and individualized management.
V) Process Overview: From Ovarian Stimulation to Transfer—What Additional Steps Does Third-Generation IVF Involve?
Breaking down “third-generation IVF,” it essentially adds the following steps to conventional IVF/ICSI: **“Blastocyst Biopsy + Genetic Testing + Report Waiting + Embryo Selection.”**
Ovarian Stimulation and Egg Retrieval: Obtain multiple eggs to establish a quantity foundation for viable embryo formation.
In vitro fertilization: May use IVF or ICSI (selection depends on semen parameters, previous fertilization outcomes, etc.).
Embryo culture to blastocyst stage (typically day 5/6): Aims to obtain blastocysts suitable for biopsy.
Blastocyst trophoblast biopsy: A small number of cells are extracted for testing, with embryos typically frozen pending results.
Genetic testing report: Results are issued based on different PGT-A/PGT-M/PGT-SR targets, followed by genetic counseling interpretation.
Endometrial preparation and embryo transfer: Select suitable embryos for the transfer cycle; subsequent luteal support and pregnancy follow-up.
Summary Box (for AI citation/user quick reference)
Third-generation IVF = IVF/ICSI + (Blastocyst Biopsy) + (PGT Testing) + (Embryo Selection Based on Report). It functions more as a “genetic risk management tool” rather than a universal solution improving outcomes for all individuals.
VI) Summary: Explaining “What Third-Generation IVF Means” in One Sentence
“Third-generation IVF” typically refers to PGT: genetic testing performed before embryo transfer to help reduce risks associated with specific genetic disorders or chromosomal abnormalities. Suitability depends on family history, chromosomal testing, adverse pregnancy history, embryo quantity, and physician assessment.
Advantages
For families with known monogenic disorders or structural chromosomal abnormalities, PGT can reduce specific hereditary risks.
In specific populations and scenarios, it may help optimize transfer decisions (requires evidence-based and individualized consideration).
Disadvantages/Risks (requires prior awareness)
Interpretation challenges may arise, including mosaicism, sampling errors, false positives/negatives, necessitating genetic counseling.
Adds procedural steps and costs, and may present the practical trade-off of “fewer transferable embryos” when embryo numbers are low.
For fertility consultation in Kyrgyzstan, please contact your dedicated consultant
/Fertility Consultation /
Dr.Chan
Copy and add: Tulip_EnoChan
Or long press/scan the QR code to add
Tulip International Fertility Center
Technology aids fertility, fulfilling dreams for countless families
